Continuation Review Report

Relevant IRB policies/procedures:

  • Continuing Review (Policy 2.2) [pdf]

[all IRB policies/procedures]

DHHS regulation 45CFR46.109(e) requires that the IRB review human subjects research at intervals appropriate to the degree of risk, but not less than once per year.

To ensure that all studies are reviewed and approved on an annual basis, the IRO will send you a reminder notice through interoffice mail several weeks before you CRR is due.

If you are doing a Clinical Research Division or Cancer Consortium study, the Protocol Office will email you all appropriate forms and current study documents, and submit your documents to the IRB.

Updated June 30, 2009

In July, the Continuation Review Report (CRR) was revised to reflect the updated policy changes on Unanticipated Problems Involving Risks to Subjects or Others (2.6), Reporting Obligations for Principal Investigators (1.11) and Noncompliance (1.9) and to incorporate users' feedback. 


The IRO recently updated the first page of the CRR for administrative purposes only (e.g. added the FHCRC Registration Identification's expiration date).  The latest version of the CRR is version 4.01, effective August 5, 2009. CRRs submitted on or after September 1, 2009 must use this version. 

Please contact James Riddle, IRO Assistant Director at 667-6501 or Denelle Reilly, IRB Operations Manager at 667-6567 with any questions/concerns regarding these changes. 

   

Submission Instructions

Full Review

Please submit the following original document.

Submit the following documents, if applicable.  Submit only the documents that the study is currently using or will use in the next approval period.

Miminal Risk

Please submit the following original documents.

Submit the following documents, if applicable.  Submit only the documents that the study is currently using or will use in the next approval period.

   

Cooperative or IRB Authorization Agreement Review

Submit one copy of:

   

Exempt Review

Original documents only.

   

Other Considerations

If you have questions regarding the Cancer Consortium IRB and/or the submission process, please go to www.cancerconsortium.org.

If you are reporting a "Closure", a CRR that includes a final summary is required. If the study was never activated (i.e., no subjects entered), you may indicate this on page 1 of the CRR.

If any documents, such as consent forms use acronyms, please be sure to spell each acronym completely when first using them. For example, Institutional Review Board (IRB).

Once the application receives final approval, the IRO will forward one copy of the approved documents to the Contact Person.

©2009 Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N., P.O. Box 19024
Seattle, WA 98109
Terms of Use & Privacy Policy
 Hutchinson Center public site Hutchinson Center public site
Hutchinson Center Extranet
DirectoryContact usMaps & directionsSearch